CDNL stock analysis 2026: Cardinal Infrastructure is growing fast enough to get your attention, but the stock has already run hard enough that you need to be careful. Full-year 2025 revenue jumped 45% to $456.0 million, backlog reached a record $682 million, and 2026 guidance implies another huge step up. The problem is simpler: this …
Is FIRE dead in 2026? No. But the easy version of FIRE is. For most people chasing financial independence, the math got harder over the last few years. Stocks are not cheap, healthcare is still a mess before Medicare, and Morningstar’s latest research says a new retiree who wants inflation-adjusted spending over 30 years should …
Neogen raised FY2026 revenue guidance after Q3, but supplier issues in Animal Safety and a rich forward P/E keep this setup balanced. Here’s the bull case, bear case, and verdict.
Bakkt has tokenization upside, but revenue fell 32% and dilution remains a risk. Here is the bull case, bear case, catalysts, and price framework.
NCNO stock analysis for 2026: strong ACV growth and improving profitability, but valuation and execution risks still matter.
PAHC stock analysis after a strong quarter: real numbers on revenue, EPS, debt, valuation, and whether the rally still has upside.
Remitly Global (NASDAQ: RELY) just posted its first profitable year, grew revenue 29%, and trades at 13x forward earnings. Sixteen analysts say buy. The average price target implies 42% upside. And almost nobody outside fintech circles is talking about it. Here’s the full breakdown. The Numbers That Matter Q4 2025 revenue came in at $442.2 …
Deluxe Corporation (NYSE: DLX) prints checks. That sentence alone is enough to make most investors scroll past. Here’s what they’d miss: payments and data now make up 47% of revenue, the data segment grew 31% last year, free cash flow just hit $175 million — a year ahead of schedule — and the stock trades …
Datavault AI posted its first profitable quarter with $33.8M in Q4 revenue. The stock is at $0.75 with a $4 analyst target. Here’s what the bull case misses.
ANI Pharmaceuticals trades at 8.4x forward earnings with Cortrophin Gel growing 76% in 2025. Now with new pharmaceutical tariff tailwinds.